ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

Chiara Gregorj; Maria R. Ricciardi; Maria T. Petrucci; Maria C. Scerpa; Fabiana De Cave; Paola Fazi; Marco Vignetti; Antonella Vitale; Marco Mancini; Giuseppe Cimino; Salvatore Palmieri; Francesco Di Raimondo; Giorgina Specchia; Francesco Fabbiano; Nicola Cantore; Federico Mosna; Andrea Camera; Mario Luppi; Luciana Annino; Eustachio Miraglia; Giuseppe Fioritoni; Francesca Ronco; Giovanna Meloni; Franco Mandelli; Michael Andreeff; Michele Milella; Robin Foà; Agostino Tafuri

doi:10.1182/blood-2006-05-021071

ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

Chiara Gregorj, Maria R. Ricciardi, Maria T. Petrucci, Maria C. Scerpa, Fabiana De Cave, Paola Fazi, Marco Vignetti, Antonella Vitale, Marco Mancini, Giuseppe Cimino, Salvatore Palmieri, Francesco Di Raimondo, Giorgina Specchia, Francesco Fabbiano, Nicola Cantore, Federico Mosna, Andrea Camera, Mario Luppi, Luciana Annino, Eustachio MiragliaGiuseppe Fioritoni, Francesca Ronco, Giovanna Meloni, Franco Mandelli, Michael Andreeff, Michele Milella, Robin Foà, Agostino Tafuri

Leukemia

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Extracellular signal-regulated kinase-1/2 (ERK1/2) is frequently found constitutively activated (p-ERK1/2) in hematopoietic diseases, suggesting a role in leukemogenesis. The aim of this study was to assess the expression and clinical role of p-ERK1/2 in adult acute lymphoblastic leukemia (ALL). In 131 primary samples from adult de novo ALL patients enrolled in the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA) Leucemia Acute Linfoide (LAL) 2000 protocol and evaluated by flow cytometry, constitutive ERK1/2 activation was found in 34.5% of cases; these results were significantly associated with higher white blood cell (WBC) values (P = .013). In a multivariate analysis, p-ERK1/2 expression was an independent predictor of complete remission achievement (P = .027). Effective approaches toward MEK inhibition need to be explored in order to evaluate whether this may represent a new therapeutic strategy for adult ALL patients.

Original language	English (US)
Pages (from-to)	5473-5476
Number of pages	4
Journal	Blood
Volume	109
Issue number	12
DOIs	https://doi.org/10.1182/blood-2006-05-021071
State	Published - Jun 15 2007

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

MD Anderson CCSG core facilities

Flow Cytometry and Cellular Imaging Facility

Access to Document

10.1182/blood-2006-05-021071

Cite this

Gregorj, C., Ricciardi, M. R., Petrucci, M. T., Scerpa, M. C., De Cave, F., Fazi, P., Vignetti, M., Vitale, A., Mancini, M., Cimino, G., Palmieri, S., Di Raimondo, F., Specchia, G., Fabbiano, F., Cantore, N., Mosna, F., Camera, A., Luppi, M., Annino, L., ... Tafuri, A. (2007). ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood, 109(12), 5473-5476. https://doi.org/10.1182/blood-2006-05-021071

Gregorj, C, Ricciardi, MR, Petrucci, MT, Scerpa, MC, De Cave, F, Fazi, P, Vignetti, M, Vitale, A, Mancini, M, Cimino, G, Palmieri, S, Di Raimondo, F, Specchia, G, Fabbiano, F, Cantore, N, Mosna, F, Camera, A, Luppi, M, Annino, L, Miraglia, E, Fioritoni, G, Ronco, F, Meloni, G, Mandelli, F, Andreeff, M, Milella, M, Foà, R & Tafuri, A 2007, 'ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia', Blood, vol. 109, no. 12, pp. 5473-5476. https://doi.org/10.1182/blood-2006-05-021071

@article{12b632994b404722b76409cdff0fac87,

title = "ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia",

abstract = "Extracellular signal-regulated kinase-1/2 (ERK1/2) is frequently found constitutively activated (p-ERK1/2) in hematopoietic diseases, suggesting a role in leukemogenesis. The aim of this study was to assess the expression and clinical role of p-ERK1/2 in adult acute lymphoblastic leukemia (ALL). In 131 primary samples from adult de novo ALL patients enrolled in the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA) Leucemia Acute Linfoide (LAL) 2000 protocol and evaluated by flow cytometry, constitutive ERK1/2 activation was found in 34.5% of cases; these results were significantly associated with higher white blood cell (WBC) values (P = .013). In a multivariate analysis, p-ERK1/2 expression was an independent predictor of complete remission achievement (P = .027). Effective approaches toward MEK inhibition need to be explored in order to evaluate whether this may represent a new therapeutic strategy for adult ALL patients.",

author = "Chiara Gregorj and Ricciardi, {Maria R.} and Petrucci, {Maria T.} and Scerpa, {Maria C.} and {De Cave}, Fabiana and Paola Fazi and Marco Vignetti and Antonella Vitale and Marco Mancini and Giuseppe Cimino and Salvatore Palmieri and {Di Raimondo}, Francesco and Giorgina Specchia and Francesco Fabbiano and Nicola Cantore and Federico Mosna and Andrea Camera and Mario Luppi and Luciana Annino and Eustachio Miraglia and Giuseppe Fioritoni and Francesca Ronco and Giovanna Meloni and Franco Mandelli and Michael Andreeff and Michele Milella and Robin Fo{\`a} and Agostino Tafuri",

year = "2007",

month = jun,

day = "15",

doi = "10.1182/blood-2006-05-021071",

language = "English (US)",

volume = "109",

pages = "5473--5476",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "12",

}

TY - JOUR

T1 - ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

AU - Gregorj, Chiara

AU - Ricciardi, Maria R.

AU - Petrucci, Maria T.

AU - Scerpa, Maria C.

AU - De Cave, Fabiana

AU - Fazi, Paola

AU - Vignetti, Marco

AU - Vitale, Antonella

AU - Mancini, Marco

AU - Cimino, Giuseppe

AU - Palmieri, Salvatore

AU - Di Raimondo, Francesco

AU - Specchia, Giorgina

AU - Fabbiano, Francesco

AU - Cantore, Nicola

AU - Mosna, Federico

AU - Camera, Andrea

AU - Luppi, Mario

AU - Annino, Luciana

AU - Miraglia, Eustachio

AU - Fioritoni, Giuseppe

AU - Ronco, Francesca

AU - Meloni, Giovanna

AU - Mandelli, Franco

AU - Andreeff, Michael

AU - Milella, Michele

AU - Foà, Robin

AU - Tafuri, Agostino

PY - 2007/6/15

Y1 - 2007/6/15

N2 - Extracellular signal-regulated kinase-1/2 (ERK1/2) is frequently found constitutively activated (p-ERK1/2) in hematopoietic diseases, suggesting a role in leukemogenesis. The aim of this study was to assess the expression and clinical role of p-ERK1/2 in adult acute lymphoblastic leukemia (ALL). In 131 primary samples from adult de novo ALL patients enrolled in the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA) Leucemia Acute Linfoide (LAL) 2000 protocol and evaluated by flow cytometry, constitutive ERK1/2 activation was found in 34.5% of cases; these results were significantly associated with higher white blood cell (WBC) values (P = .013). In a multivariate analysis, p-ERK1/2 expression was an independent predictor of complete remission achievement (P = .027). Effective approaches toward MEK inhibition need to be explored in order to evaluate whether this may represent a new therapeutic strategy for adult ALL patients.

AB - Extracellular signal-regulated kinase-1/2 (ERK1/2) is frequently found constitutively activated (p-ERK1/2) in hematopoietic diseases, suggesting a role in leukemogenesis. The aim of this study was to assess the expression and clinical role of p-ERK1/2 in adult acute lymphoblastic leukemia (ALL). In 131 primary samples from adult de novo ALL patients enrolled in the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA) Leucemia Acute Linfoide (LAL) 2000 protocol and evaluated by flow cytometry, constitutive ERK1/2 activation was found in 34.5% of cases; these results were significantly associated with higher white blood cell (WBC) values (P = .013). In a multivariate analysis, p-ERK1/2 expression was an independent predictor of complete remission achievement (P = .027). Effective approaches toward MEK inhibition need to be explored in order to evaluate whether this may represent a new therapeutic strategy for adult ALL patients.

UR - http://www.scopus.com/inward/record.url?scp=34249995742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249995742&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-05-021071

DO - 10.1182/blood-2006-05-021071

M3 - Article

C2 - 17351113

AN - SCOPUS:34249995742

SN - 0006-4971

VL - 109

SP - 5473

EP - 5476

JO - Blood

JF - Blood

IS - 12

ER -

ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this